Home ›
Entities
› academia
› Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial
Research article (The Lancet Microbe, 2023) · cited 25× · AI/ML
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial
Summary
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial is a scholarly article[1].
Key Facts
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial. Retrieved May 24, 2026, from https://4ort.xyz/entity/comparative-antibody-and-cell-mediated-immune-responses-reactogenicity-and-efficacy-of-homologous-and-heterologous-boost
MLA“Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/comparative-antibody-and-cell-mediated-immune-responses-reactogenicity-and-efficacy-of-homologous-and-heterologous-boost.
BibTeX@misc{4ortxyz_comparative-antibody-and-cell-mediated-immune-responses-reactogenicity-and-efficacy-of-homologous-and-heterologous-boost_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial}}, year = {2026}, url = {https://4ort.xyz/entity/comparative-antibody-and-cell-mediated-immune-responses-reactogenicity-and-efficacy-of-homologous-and-heterologous-boost}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial — https://4ort.xyz/entity/comparative-antibody-and-cell-mediated-immune-responses-reactogenicity-and-efficacy-of-homologous-and-heterologous-boost (retrieved 2026-05-24)
